secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2026-09-14T13:28:02+00:00
Accession:  0001493152-26-042506
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology and Nerviano settle litigation, amend onvansertib license
--------------------------------------------------------------------------

- Settlement resolves Cardiff v. Nerviano (Case No. 3:26-cv-03131-RBM-JLB) with mutual releases; no money exchanged
- Amended license adds exclusivity framework, additional license fee on annual net sales, and development milestones
- Nerviano gets board observer plus Scientific Advisory Board seat; revised post-termination royalty tiers added
- Revised assignment provision: Cardiff owes NMS percentage of proceeds if change of control before Phase III data readout
- Amendment effective upon dismissal with prejudice; existing license otherwise remains in force

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000149315226042506/0001493152-26-042506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000149315226042506/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-042506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer